Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent.
ADCC
HIV
broadly neutralizing antibodies
gp120
gp41
neutralization
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
06 Jun 2022
06 Jun 2022
Historique:
received:
16
05
2022
revised:
30
05
2022
accepted:
02
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Broadly neutralizing antibodies (bNAbs) offer promising opportunities for preventing HIV-1 infection. The protection mechanisms of bNAbs involve the Fc domain, as well as their Fab counterpart. Here, different bNAb isotypes including IgG1, IgA1, IgA2, and IgA122 (IgA2 with the hinge of IgA1) were generated and then produced in CHO cells. Their ability to neutralize pseudovirus and primary HIV-1 isolates were measured, as well as their potential ADCC-like activity using a newly developed assay. In our work, gp41-specific IgA seems to be more efficient than IgG1 in inducing ADCC-like activity, but not in its virus neutralization effect. We show that either gp120-specific IgA or IgG1 isotypes are both efficient in neutralizing different viral strains. In contrast, gp120-specific IgG1 was a better ADCC-like inducer than IgA isotypes. These results provide new insights into the neutralization and ADCC-like activity of different bNAbs that might be taken into consideration when searching for new treatments or antibody-based vaccines.
Identifiants
pubmed: 35746511
pii: vaccines10060903
doi: 10.3390/vaccines10060903
pmc: PMC9227833
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS Pathog. 2020 Feb 24;16(2):e1008083
pubmed: 32092122
Curr Opin HIV AIDS. 2017 May;12(3):209-215
pubmed: 28422785
J Immunol. 2007 Sep 1;179(5):3144-52
pubmed: 17709529
Trends Immunol. 2008 Feb;29(2):91-7
pubmed: 18191616
Immunity. 2011 Feb 25;34(2):269-80
pubmed: 21315623
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12680-5
pubmed: 22723360
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3739-44
pubmed: 18322015
Retrovirology. 2014 Dec 14;11:109
pubmed: 25499540
Virology. 2003 Sep 30;314(2):636-49
pubmed: 14554091
Front Immunol. 2018 Mar 29;9:244
pubmed: 29651286
Cell. 2014 Sep 11;158(6):1243-1253
pubmed: 25215485
J Virol. 2003 Apr;77(7):4095-103
pubmed: 12634368
AIDS. 2013 Jun 1;27(9):F13-20
pubmed: 23775002
EBioMedicine. 2016 Dec;14:97-111
pubmed: 27919754
PLoS Pathog. 2019 Dec 16;15(12):e1008064
pubmed: 31841557
PLoS Pathog. 2020 Dec 14;16(12):e1009103
pubmed: 33315937
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9019-24
pubmed: 23661056
Nature. 2012 Nov 15;491(7424):406-12
pubmed: 23151583
Front Immunol. 2020 Jun 09;11:1141
pubmed: 32582208
J Virol. 2016 Jun 10;90(13):6127-6139
pubmed: 27122574
Nat Commun. 2016 Mar 03;7:10844
pubmed: 26936020
J Virol. 1993 Dec;67(12):7060-6
pubmed: 8230430
J Virol. 1995 Jan;69(1):39-48
pubmed: 7983734
Mucosal Immunol. 2017 Jan;10(1):228-237
pubmed: 27072605
Nat Immunol. 2000 Nov;1(5):441-6
pubmed: 11062505
mBio. 2019 Jul 2;10(4):
pubmed: 31266872
Nat Struct Mol Biol. 2013 Jul;20(7):804-13
pubmed: 23708607
Immunol Rev. 2017 Jan;275(1):245-261
pubmed: 28133811
Cell Host Microbe. 2020 Jun 10;27(6):963-975.e5
pubmed: 32315598
Immunity. 2005 Feb;22(2):163-73
pubmed: 15723805
Immunity. 2016 Jan 19;44(1):21-31
pubmed: 26777395
AIDS Res Hum Retroviruses. 2003 Jul;19(7):597-607
pubmed: 12908937
J Virol. 1994 Mar;68(3):1342-9
pubmed: 8107199
J Virol. 2014 Jan;88(2):1249-58
pubmed: 24227838
AIDS. 2013 Mar 13;27(5):717-30
pubmed: 23719346
Virology. 2004 Mar 30;321(1):8-22
pubmed: 15033560
Cell Rep. 2020 Nov 24;33(8):108430
pubmed: 33238131
J Immunol. 2010 Apr 1;184(7):3648-55
pubmed: 20208001
J Acquir Immune Defic Syndr. 2017 May 1;75(1):118-127
pubmed: 28177967
Immunol Rev. 2013 Jul;254(1):225-44
pubmed: 23772623
Curr Protoc Immunol. 2005 Jan;Chapter 12:Unit 12.11
pubmed: 18432938